CRISPR/Cas9-targeted correction of heterozygous mutations in human preimplantation embryos

Case ID:
2391
Web Published:
8/4/2017
Description:

Technology Overview

More than 10,000 monogenic inherited disorders have been identified, affecting millions of people worldwide. Among these are the autosomal dominant mutations, where inheritance of a single copy of a defective gene can result in clinical symptoms. Dominant mutations that manifest as late-onset adult disorders include BRCA1 and BRCA2, associated with a high risk of breast and ovarian cancers and MYBPC3 causing hypertrophic cardiomyopathy (HCM).  OHSU has a proprietary method to correct a mutant allele of a gene of interest in an embryo allowing homology-directed repair to prevent transmission of monogenic inherited disorders such as HCM.

Licensing Opportunity

This technology is available for licensing and/or co-development.

Patent Information:
Category(s):
Therapeutics
For Information, Contact:
Anne Carlson
Assoc Dir, Tech Dev & Licensing
Oregon Health & Science University
503-494-7809
carlsann@ohsu.edu
Inventors:
Shoukhrat Mitalipov
Nuria Marti-Gutierrez
Keywords:
Therapeutics - Reproductive
© 2024. All Rights Reserved. Powered by Inteum